csirt@kutim:~/threat-intel/cve/CVE-2025-25186

Katalog CVE

CVSS 6.5 · Medium EPSS 0,63%

Kerentanan Uncontrolled Resource Consumption. Skor CVSS 3.1 6.5 (Medium) menurut github.com.

Deskripsi (NVD)

Net::IMAP implements Internet Message Access Protocol (IMAP) client functionality in Ruby. Starting in version 0.3.2 and prior to versions 0.3.8, 0.4.19, and 0.5.6, there is a possibility for denial of service by memory exhaustion in `net-imap`'s response parser. At any time while the client is connected, a malicious server can send can send highly compressed `uid-set` data which is automatically read by the client's receiver thread. The response parser uses `Range#to_a` to convert the `uid-set` data into arrays of integers, with no limitation on the expanded size of the ranges. Versions 0.3.8, 0.4.19, 0.5.6, and higher fix this issue. Additional details for proper configuration of fixed versions and backward compatibility are available in the GitHub Security Advisory.

Rincian

Terbit di NVD
10 Februari 2025
Terakhir diubah
17 Juni 2026
Status NVD
Deferred
CVSS 3.1
6.5 (Medium), sumber github.com
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:N/I:N/A:H · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-400: Uncontrolled Resource Consumption
CWE-405: Asymmetric Resource Consumption (Amplification)
CWE-409: Improper Handling of Highly Compressed Data (Data Amplification)
CWE-770: Allocation of Resources Without Limits or Throttling
CWE-789: Memory Allocation with Excessive Size Value
CWE-1287: Improper Validation of Specified Type of Input
EPSS (30 hari)
0,63% peluang dieksploitasi; lebih tinggi dari 48,8% CVE lain

Produk dan versi terdampak

NVD belum mencantumkan data produk (CPE) untuk CVE ini. Produk yang terdampak biasanya disebut di deskripsi dan di advisory vendor pada daftar referensi.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:11 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.